|
|
|
Thread Tools | Search this Thread | Display Modes |
#1
|
|||
|
|||
OT: Anti-Obesity Drug that I've been working on enters clinic
The anti-obesity drug that I've been working on for a number of years has just entered human clinical trials. Here are the press releases:
http://www.peptimmune.com/pep080904.htm "Peptimmune Announces Start of Phase I Trial for Obesity August 9, 2004 CAMBRIDGE, Mass. - Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability and pharmacokinetics of GT389-255, a lipase inhibitor conjugated to a fat binding polymer for the treatment of obesity. The Phase I single ascending dose (SAD) double blind placebo controlled randomized study will involve 48 healthy male volunteers who will receive the drug in six escalating dose cohorts. Later in 2004, the SAD study will be followed by a multiple ascending dose Phase I study (MAD). If Phase I development is successful, Peptimmune anticipates launching a Phase II trial in patients with obesity in 2005. GT389-255 is a novel conjugate of a pancreatic lipase inhibitor and a fat binding hydrogel polymer. It acts within the gastro-intestinal tract to prevent fat digestion and is expected to have fewer side-effects than currently marketed therapies. The reduction in caloric intake and lowering of fat absorption may lead to weight loss, with potential concomitant improvement in both diabetic and cardiovascular risk profiles. GT389-255 has been evaluated in a number of preclinical studies, including investigational new drug-enabling toxicology studies. Peptimmune licensed GT389-255 from Genzyme Corporation earlier this year. "The commencement of this clinical trial is an important milestone for the development of GT389-255 and for the company," stated Thomas Mathers, President of Peptimmune. "The goal for GT389-255 is the development of a lipase inhibitor/fat binder that provides inhibition of fat absorption and associated weight loss, but mitigates the gastrointestinal side effects associated with undigested trigylerides in the colon". Obesity is nearing epidemic proportions in the developed world. The prevalence of obesity is increasing worldwide, with 2003 World Health Organization estimates that over 300 million people are affected. Since 1980, the number of adults in the US has doubled and the number of obese teens has tripled. Obesity is associated with an increased risk of serious metabolic diseases, including cardiovascular disease, Type 2 diabetes, hypertension, stroke, dyslipidemia, and osteoarthritis. Approximately 300,000 deaths per year are attributed to being overweight or obese. Obesity exerts a significant burden on the health care system. Diet and exercise alone have failed to treat this growing epidemic. Currently approved pharmacological therapies for weight loss have had limited success due to insufficient efficacy and burdensome, unpleasant side effects and safety concerns. New therapies with improved tolerability and fewer side effects are needed not only to treat obesity, but also to prevent the significant co-morbidities associated with it, such as diabetes, hypertension and cardiovascular disease. " and http://www.peptimmune.com/pep051004.htm "Peptimmune is Granted Exclusive License from Genzyme to Develop and Commercialize Treatment for Metabolic Diseases including Obesity May 10, 2004 CAMBRIDGE, Mass. - Genzyme Corporation and Peptimmune, Inc. today announced that Genzyme has granted an exclusive worldwide license to Peptimmune to develop and market a Genzyme investigational drug candidate for the treatment of obesity and other metabolic disease indications. Peptimmune plans to file an IND with the U.S. Food and Drug Administration to begin clinical trials of the drug later this year. Under the agreement, Genzyme grants Peptimmune exclusive rights to develop, manufacture and commercialize GT389-255, in exchange for royalties, in addition to shared milestones and payments if the program is partnered further. Financial details were not disclosed. "The acquisition of a product in the metabolic disease field that could enter the clinic in 2004 broadens and diversifies Peptimmune's pipeline," stated Tom Mathers, president of Peptimmune. "It accelerates our evolution from a research and discovery stage company, to a fully integrated biopharmaceutical company. The prospect of a new treatment for obesity offers hope for the millions of people suffering from this worldwide epidemic." The investigational drug candidate, GT389-255, has a dual mechanism of action, serving as a pancreatic lipase inhibitor and a fat-binder. It acts within the gastro-intestinal tract to prevent fat digestion and is expected to have fewer side-effects than currently marketed therapies. GT389-255 has been evaluated in a number of preclinical studies, including investigational new drug-enabling toxicology studies. "We have discovered a very innovative treatment for obesity that has the potential to address a very serious and growing worldwide public health problem," stated Ted Sybertz, Ph.D., senior vice president and general manager of Genzyme Drug Discovery and Development. "However, because of its broad physician call-point, obesity is not a strategic fit for Genzyme. Given Peptimmune's experienced management team, clinical development expertise in both autoimmune and metabolic disease, and their commitment to moving this program forward, we think they are an excellent partner." The Genzyme drug discovery effort that developed the anti-obesity program has drawn upon the company's extensive expertise in developing compounds to treat metabolic disease and its world-renowned reputation in polymer chemistry. Two polymer products have been brought to market, Renagel® (sevelamer hydrochloride), a calcium-free, metal-free phosphate binder for patients with end-stage renal disease, and WelChol® (colesevelum hydrocholoride), a cholesterol-lowering agent. A third polymer, tolevamer, has recently completed Phase 2 clinical trials for the treatment of C. difficile associated diarrhea. These polymer therapies are not absorbed and all act within the GI tract. Obesity - An Expanding Epidemic Obesity is a global healthcare issue that is associated with an increased risk of serious metabolic diseases, including cardiovascular disease, Type 2 diabetes, hypertension, stroke, dyslipidemia, and osteoarthritis. Published prevalence rates indicate that more than 180 million people in the United States and Europe are obese, and the number of obese individuals continues to increase dramatically worldwide. A 1999 article published in the Journal of the American Medical Association estimates that there are some 300,000 deaths per year in the United States that are attributed to overweight and obesity. According to data released by the U.S. Department of Health and Human Services, the direct medical costs to the U.S. population that were attributed to obesity totaled $117 billion in 2000. About Genzyme Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company's broad product portfolio is focused on rare genetic disorders, renal disease, osteoarthritis and immune-mediated diseases, and includes an industry-leading array of diagnostic products and services. Genzyme's commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need. More than 6,300 Genzyme employees in offices around the globe serve patients in over 80 countries. About Peptimmune Peptimmune, Inc. is a privately held biotechnology company focused on development of therapeutics for the treatment of autoimmune and metabolic diseases. The company is led by an experienced management team with a track record of building commercial biotechnology companies. Peptimmune has one product in clinical trials for the treatment of pemphigus vulgaris, and a pipeline of late stage preclinical products for the treatment of autoimmune and metabolic diseases including, multiple sclerosis, rheumatoid arthritis and obesity. For information, access our website at http://www.peptimmune.com. "
__________________
Randy Holmes-Farley |
#2
|
|||
|
|||
Congratulations! Now, does this work for fat between the ears? I'm looking for a solution...
__________________
Jonathan Bertoni |
#3
|
|||
|
|||
Congratulations!!! I hope the trials are successful.
__________________
Curt If you're not part of the solution, you're part of the precipitate. |
#4
|
|||
|
|||
My company is making a drug that fattens you up. We've got it all covered now.
__________________
"nobody tests for saliferts anymore" |
#5
|
|||
|
|||
Cool.
study will involve 48 healthy male volunteers Any particular reasons to use only males?
__________________
"I'm a big dumb stupid head." - Beerbutt Proud owner of the very rare YET (Yellow Elephantis Tang) from the Lord Bibah Islands. "LOL, well I have no brain apparently. " - dc (Debi) |
#6
|
|||
|
|||
I'm not permitted to make any public comments on our clinical trials (and don't know the precise answer in our case anyway), but often companies run the early phases of clinical trials on men only to avoid any concerns about possible harm to fetuses of women that may be pregnant. Additionally, lots of pregnancies go bad for unknown reasons. If that happens in a small clinical trial, the drug may get blamed even if it had nothing to do with it.
__________________
Randy Holmes-Farley |
#7
|
|||
|
|||
That makes sense.
Thanks, learned something new today.
__________________
"I'm a big dumb stupid head." - Beerbutt Proud owner of the very rare YET (Yellow Elephantis Tang) from the Lord Bibah Islands. "LOL, well I have no brain apparently. " - dc (Debi) |
#8
|
|||
|
|||
Hmm, I don't remeber you asking us for permisson to use our military codes
SAD = Strategic Air Defense MAD = Mutually Assured Destruction Hmm, on second thought maybe that is what you guys really mean Congrats Randy Hab Any particular reasons to use only males? I think Randy is pregedous or the wife has something to a say about it or Randy is trying to tell us something about himself in the near future. Edit Ok, now I see why good idea
__________________
If you See Me Running You Better Catch-Up An explosion can be defined as a loud noise, accompanied by the sudden going away of things, from a place where they use to be. |
#9
|
|||
|
|||
You work too !
With the fast replies and the sheer volume of stuff you do on RC I thought you must be retired or something You must be one busy guy. |
#10
|
|||
|
|||
Looks like a very promising new development. I am forwarding the info to my brother in law who is a research Endocrine Doc. Should be right up his alley.
__________________
"You call someplace paradise, kiss it goodbye" The Last Resort, The Eagles |
#11
|
|||
|
|||
Quote:
Not that I agree with the whole line of reasoning- most all research in any number of health related issues is conducted solely on men. I could open up the whole "men run the companies that fund the research that is controlled by men" can of worms but that would be grossly unfair to Randy who is but a player in the game. Sorry to rant- guess I'm "hormonally unstable". That's what 5+ years of hot flashes can do to a person. Hey- the title said OT!!
__________________
The answer to every single question in reefkeeping begins with "It depends..." |
#12
|
|||
|
|||
You work too !
I can answer that, very little, he is always on vacation, like right now again He has more threads on I'm going on vacation than I have posts here Hey- the title said OT!! OT =Over-Time @ work, a word Randy has never heard of, except when he sends me my pay check, he always wants to know what it stands for
__________________
If you See Me Running You Better Catch-Up An explosion can be defined as a loud noise, accompanied by the sudden going away of things, from a place where they use to be. |
#13
|
|||
|
|||
FWIW, the early planning and design of our clinical trial of our obesity drug was carried out by a woman MD.
Later stage clinical trials for all drugs not aimed exclusively for men certainly include large numbers of women.
__________________
Randy Holmes-Farley |
#14
|
|||
|
|||
I can answer that, very little, he is always on vacation, like right now again
Yes, a couple more days of vacation......
__________________
Randy Holmes-Farley |
#15
|
|||
|
|||
Hmmmmm, knowing that you are a reefer it would not surprise me if it is just some form of dried corals:
FOOD CONTAINING CORAL Patent number: JP10276722 Publication date: 1998-10-20 Inventor: HIROTA YUJI Applicant: M P G KK Classification: - international: A23L1/304 - european: Application number: JP19970102796 19970404 Priority number(s): Abstract of JP10276722 PROBLEM TO BE SOLVED: To obtain a food having not only activities for inhibiting generation of cancer cells but also activities for neutralizing and degrading fat and for excreting wastes in a body. SOLUTION: This food containing coral is obtained by adding the coral dried and formed into the powdery one to a food (including a drink) to provide the objective food having not only activities for inhibiting generation of cancer cells but also activities for neutralizing and degrading fat and for excreting wastes in a body.
__________________
"I'm a big dumb stupid head." - Beerbutt Proud owner of the very rare YET (Yellow Elephantis Tang) from the Lord Bibah Islands. "LOL, well I have no brain apparently. " - dc (Debi) |
#16
|
|||
|
|||
If ground up corals were in my food, I think I would loose weight.
__________________
Randy Holmes-Farley |
#17
|
|||
|
|||
Yeah !
All those coral toxins might be just the ticket. You eat it, you spend the next day barfing and with diarrhea, you lose an incredible amount of weight in a short time |
#18
|
|||
|
|||
Sounds like an improved Xenical! If it works, and doesn't cause nasty diarrhea, could be a breakthrough drug.
John
__________________
"Do or do Not, there is no Try" ---Yoda |
#19
|
|||
|
|||
Sounds like an improved Xenical! If it works, and doesn't cause nasty diarrhea,
Yes, exactly.
__________________
Randy Holmes-Farley |
#20
|
|||
|
|||
So...Randy, is THAT how you lost the weight!
|
#21
|
|||
|
|||
I wish it were, because then I probably wouldn't be gaining it back as I am now.
__________________
Randy Holmes-Farley |
#22
|
|||
|
|||
Re: OT: Anti-Obesity Drug that I've been working on enters clinic
Quote:
I hope that you're a principal in the company - so you can retire and devote even more time to this forum! Congratulatons! Bob D. |
#23
|
|||
|
|||
I always thought someone could do something like this with my wife's cooking. Hmmm...Randys been very busy since we had him over for dinner......
__________________
A good plan today is better than a great plan tomorrow. |
#24
|
|||
|
|||
I hope that you're a principal in the company - so you can retire and devote even more time to this forum!
I was the second employee of GelTex, but Genzyme bought us a few years back for $1.25 billion. I'm now VP of Chemical Research at Genzyme doing drug discovery chemistry. Genzyme is a fairly large company (thousands of employees and more than a billion dollars in sales each year), so I am nothing that would be called a "principle" in the company, nor do I have much ongoing financial interest in the drug itself since we licensed it out. Mostly just hope, and hopefully, satisfaction if it works. I always thought someone could do something like this with my wife's cooking. Hmmm...Randys been very busy since we had him over for dinner......
__________________
Randy Holmes-Farley |
#25
|
|||
|
|||
that drug has been on the market for years randy , its called cocaine i think
|
Thread Tools | Search this Thread |
Display Modes | |
|
|